110 related articles for article (PubMed ID: 6607493)
1. [Innovations in the determination of antinuclear antibodies and the motility of polymorphonuclear leukocytes in rheumatic diseases].
Zivković M; Obradović M
Reumatizam; 1983; 30(5-6):123-5. PubMed ID: 6607493
[No Abstract] [Full Text] [Related]
2. The current use and interpretation of rheumatologic tests.
Moder KG; Mason TG
Adolesc Med; 1998 Feb; 9(1):25-34, v. PubMed ID: 10961249
[TBL] [Abstract][Full Text] [Related]
3. Detection of antinuclear factor activity in rheumatic diseases.
Austad WR
Univ Mich Med Cent J; 1967; 33(6):259-62. PubMed ID: 4170563
[No Abstract] [Full Text] [Related]
4. [Scleroderma. Which tests should be performed?].
Crickx B; Lazareth I
Ann Dermatol Venereol; 1990; 117(1):83-6. PubMed ID: 2181910
[No Abstract] [Full Text] [Related]
5. Laboratory diagnosis of systemic rheumatic disease.
Maehara KT
Am J Med Technol; 1983 Jul; 49(7):477-81. PubMed ID: 6194686
[No Abstract] [Full Text] [Related]
6. Antinuclear antibodies in dermatology.
Heffernan MP; Do JH; Mehta J
Semin Cutan Med Surg; 2001 Mar; 20(1):2-13. PubMed ID: 11308133
[TBL] [Abstract][Full Text] [Related]
7. [Polymorphonuclear chemotaxis and serum autoantibodies in aging (author's transl)].
Sorger E; Pehamberger H
Wien Klin Wochenschr; 1981 Jul; 93(14):463-5. PubMed ID: 6973897
[TBL] [Abstract][Full Text] [Related]
8. Anticentromere antibodies: clinical and biological significance.
Fritzler MJ; Ayer LM
J Rheumatol; 1982; 9(4):489-90. PubMed ID: 6982333
[No Abstract] [Full Text] [Related]
9. [The meaning of antinuclear antibodies and of the ASL O titer in rheumatic diseases (author's transl)].
Zirm M
Klin Monbl Augenheilkd; 1979 Jan; 174(1):82-7. PubMed ID: 311873
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of common serum rheumatologic tests.
Lane SK; Gravel JW
Am Fam Physician; 2002 Mar; 65(6):1073-80. PubMed ID: 11925083
[TBL] [Abstract][Full Text] [Related]
11. [Anticentromere antibodies. Diagnostic and prognostic value].
Meyer O; Haïm T
Nouv Presse Med; 1982 Oct; 11(39):2891-4. PubMed ID: 6755388
[TBL] [Abstract][Full Text] [Related]
12. [Results of studies using the indirect immunofluorescence methods (antinuclear factors) in various rheumatic entities].
Ripoll Gómez M
Rev Esp Reum Enferm Osteoartic; 1975; 18(1):65-9. PubMed ID: 1094511
[No Abstract] [Full Text] [Related]
13. New studies on rheumatic diseases.
Tan EW
Proc Annu Meet Med Sect Am Counc Life Insur; 1978; ():11-28. PubMed ID: 384397
[No Abstract] [Full Text] [Related]
14. [Antinuclear autoantibodies].
Röther E; Peter HH
Internist (Berl); 1995 Mar; 36(3):277-81. PubMed ID: 7737821
[No Abstract] [Full Text] [Related]
15. [Immunodiagnosis of rheumatic diseases].
Maĭtveĭkov GP; Koshelev VK; Nazarov IuM; Kaliia EC; Dosin IuM
Ter Arkh; 1981; 53(5):87-93. PubMed ID: 6170125
[No Abstract] [Full Text] [Related]
16. [Importance of certain laboratory indicators for determination of the activity of systemic scleroderma].
Shiapak EA; Drampian FS; Kessel' VP; Aznaurian AV; Lobanova IN
Zh Eksp Klin Med; 1973; 13(3):96-100. PubMed ID: 4599068
[No Abstract] [Full Text] [Related]
17. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests.
Kavanaugh AF; Solomon DH;
Arthritis Rheum; 2002 Oct; 47(5):546-55. PubMed ID: 12382306
[No Abstract] [Full Text] [Related]
18. Rheumatic diseases.
Fukunaga FH
Hawaii Med J; 1984 Nov; 43(11):416. PubMed ID: 6334674
[No Abstract] [Full Text] [Related]
19. The antinuclear antibody test. When is a positive result clinically relevant?
Thomas C; Robinson JA
Postgrad Med; 1993 Aug; 94(2):55-8, 63, 66. PubMed ID: 8341626
[TBL] [Abstract][Full Text] [Related]
20. [Immunologic findings in progressive scleroderma--diagnostic and nosologic significance].
Sönnichsen N; Brenke A; Barthelmes H; Albrecht-Nebe H; Diezel W
Dermatol Monatsschr; 1983 Jun; 169(6):385-93. PubMed ID: 6603989
[No Abstract] [Full Text] [Related]
[Next] [New Search]
